23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

C. Watera; J. Nakiyingi; G. Miiro; R. Muwonge; J. A. G. Whitworth; C.F. Gilks; Neil French

doi:10.1097/00002030-200405210-00018

23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

C. Watera
, J. Nakiyingi
, G. Miiro
, R. Muwonge
, J. A. G. Whitworth
, C.F. Gilks
, Neil French

Liverpool School of Tropical Medicine

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Article › peer-review

65 Citations (Scopus)

Abstract

23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

Original language	English
Pages (from-to)	1210-1213
Number of pages	4
Journal	AIDS
Volume	18
Issue number	8
DOIs	https://doi.org/10.1097/00002030-200405210-00018
Publication status	Published - 21 May 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/00002030-200405210-00018

Cite this

@article{ae4758506c704f2b855eef598faab445,

title = "23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort",

abstract = "23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95\% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.",

author = "C. Watera and J. Nakiyingi and G. Miiro and R. Muwonge and Whitworth, \{J. A. G.\} and C.F. Gilks and Neil French",

year = "2004",

month = may,

day = "21",

doi = "10.1097/00002030-200405210-00018",

language = "English",

volume = "18",

pages = "1210--1213",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

AU - Watera, C.

AU - Nakiyingi, J.

AU - Miiro, G.

AU - Muwonge, R.

AU - Whitworth, J. A. G.

AU - Gilks, C.F.

AU - French, Neil

PY - 2004/5/21

Y1 - 2004/5/21

N2 - 23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

AB - 23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

U2 - 10.1097/00002030-200405210-00018

DO - 10.1097/00002030-200405210-00018

M3 - Article

SN - 0269-9370

VL - 18

SP - 1210

EP - 1213

JO - AIDS

JF - AIDS

IS - 8

ER -

23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this